Literature DB >> 29431733

Cardiovascular outcome trials of diabetes drugs: lessons learned.

Simeon I Taylor1, Bruce R Leslie2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29431733      PMCID： PMC5824867          DOI： 10.1172/JCI99820

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  26 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

3.  Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Rury R Holman; M Angelyn Bethel; Robert J Mentz; Vivian P Thompson; Yuliya Lokhnygina; John B Buse; Juliana C Chan; Jasmine Choi; Stephanie M Gustavson; Nayyar Iqbal; Aldo P Maggioni; Steven P Marso; Peter Öhman; Neha J Pagidipati; Neil Poulter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

4.  Editorials: Statistical problems in clinical trials: the UGDP study revisited.

Authors:  S S Schor
Journal:  Am J Med       Date:  1973-12       Impact factor: 4.965

5.  Liraglutide and Renal Outcomes in Type 2 Diabetes.

Authors:  Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

6.  Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?

Authors:  Robert J Smith; Allison B Goldfine; William R Hiatt
Journal:  Diabetes Care       Date:  2016-05       Impact factor: 19.112

7.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

Authors:  J Michael Gaziano; Anthony H Cincotta; Aaron Vinik; Lawrence Blonde; Nancy Bohannon; Richard Scranton
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079
View more
  5 in total

Review 1.  Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.

Authors:  Jung-Im Shin
Journal:  Curr Diab Rep       Date:  2019-07-08       Impact factor: 4.810

Review 2.  Basic Mechanisms of Diabetic Heart Disease.

Authors:  Rebecca H Ritchie; E Dale Abel
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

Review 3.  Pharmacological treatment of hyperglycemia in type 2 diabetes.

Authors:  Simeon I Taylor; Zhinous Shahidzadeh Yazdi; Amber L Beitelshees
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

4.  Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.

Authors:  Maria Ida Maiorino; Miriam Longo; Lorenzo Scappaticcio; Giuseppe Bellastella; Paolo Chiodini; Katherine Esposito; Dario Giugliano
Journal:  Cardiovasc Diabetol       Date:  2021-10-18       Impact factor: 9.951

5.  The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients.

Authors:  Simeon I Taylor
Journal:  Diabetes Care       Date:  2020-10       Impact factor: 19.112
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.